Indication

Ciprofloxacin is used in adults for the treatment of urinary tract infections, lower respiratory tract infections and skin & skin structure infections, bone and joint infections, and G.I. infections (enteric fever, infectious diarrhea) caused by susceptible gram-negative and gram-positive aerobic bacteria. It is also used for the treatment of uncomplicated urethral gonorrhea caused by penicillinase and non-penicillinase-producing Neisseria gonorrhoeae.


Dosage & Administration

Inflections Type of Severity Unit Dose Frequency Duration
Unit Tract
Mild/Moderate
Severe/Complicated
Acute Systitis
250 mg
500 mg
500 mg
b.i.d
b.i.d
b.i.d
7-14 days
7-14 days
3 days
Chronic Bacterial
Prostatis
Mild/Moderate 500 mg b.i.d 28 days
Lower Respiratory
Tract
Mild/Moderate
Severe/Complicated
500 mg
750 mg
b.i.d
b.i.d
7-14 days
7-14 days
Acute Sinusitis Mild/Moderate 500 mg b.i.d 10 days
Skin & Skin
Structure
Mild/Moderate
Severe/Complicated
500 mg
750 mg
b.i.d
b.i.d
7-14 days
7-14 days
Bone and Joint
Mild/Moderate
Severe/Complicated
500 mg
750 mg
b.i.d
b.i.d
>=4-6 Weeks
>=4-6 days
Intra-Abdominal Complicated 500 mg b.i.d 7-14 days
Infectious Diarrhea Mild/Moderate/Severe 500 mg b.i.d 5-7 days
Typhoid Fever Mild/Moderate 500 mg b.i.d 10 days
UrethralCervical
Gonococcal
Infections
Ubncomplicated 250 mg Single dose Single dose
Inhalational
Anthrax
( Post-exposure )
Adult
Pediatric
500 mg
15 mg/kg/dose;
not to exceed
500 mg/dose
b.i.d
b.i.d
60 days
60 days

Generally Ciprofloxacin should be continued for at least 2 days after the signs and symptoms have disappeared, except for inhalational anthrax (post-exposure). Patients whose therapy is started with Ciprofloxacin I.V. may be switched to Ciprofloxacin tablets or suspension when clinically indicated at the discretion of the physician.

Pediatric Patient & Adolescents (1 to 17 years of age)
Complicated Urinary Tract Infections and Pyelonephritis due to Escherichia coli.

Inflections Rule of Administration Dose (mg/kg) Frequency Duration
Complicated
Urinary Tract or
Pyelonephritis
Oral
Intravenous
10-20 mg/kg
(Max. 750 mg/dose; not
to be exceeded even in
patients weighing >51 kg)
6-10 mg/kg
(Max. 400 mg/dose; not
to be exceeded even in
patients weighing >51 kg)
b.i.d
Every 8 hours
10-12 days
Inhalational
Anthrax
(Post-exposure)
Oral
Intravenous
15 mg/kg
(Max. 500 mg/dose)
10 mg/kg
(Max. 400 mg/dose)
b.i.d
b.i.d
60 days


Precautions

Ciprofloxacin should be used with caution in patients with a history of convulsive disorders. Crystalluria related to the use of Ciprofloxacin has been observed very rarely. Patients receiving Ciprofloxacin should be well hydrated and excessive alkalinity of the urine should be avoided. Use in Pregnancy: As with other quinolones, Ciprofloxacin has been shown to cause arthropathy in immature animals and therefore its use during pregnancy is not recommended. Use in Lactation: Studies in rats have indicated that Ciprofloxacin is secreted in milk; administration to nursing mothers is thus not recommended.

 

Direction for Reconstitution
CivoxTM Suspension: The small bottle contains the pellets; the large bottle contains the diluent. Pour the pellets (from small bottle) completely into the large bottle of diluent. Do not add water to the suspension. Close the bottle tightly & shake vigorously until it is properly mixed. The suspension is ready for use. Shake the bottle well before each use.


Product Details


Related Products

Cefobac

Cefuroxime
Antibiotics & Antiviral

Eracef

Ceftriaxone
Antibiotics & Antiviral

Zemicef

Cefixime
Antibiotics & Antiviral

Zidicef

Ceftazidime
Antibiotics & Antiviral

Cefomin

Cefpodoxime
Antibiotics & Antiviral